Q-omics provides the consensus-scored WASHC2A profile across patient tissues and cancer cell-line models. WASHC2A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WASHC2A is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, WASHC2A RNA expression shows 19,482 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where WASHC2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WASHC2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WASHC2A survival associations across molecular data types. WASHC2A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WASHC2A RNA expression–survival associations across cancer types. High WASHC2A expression shows unfavorable associations in KICH and LIHC, but favorable associations in KIRC, SCLC, SKCM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WASHC2A RNA expression.
This table summarizes WASHC2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for WASHC2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WASHC2A shows lower tumor expression in COAD, KICH, LUSC and LUAD and higher tumor expression in LIHC and HNSC. The LIHC box plot shows higher WASHC2A RNA expression in tumor versus normal tissue (log2 FC = +1.591, t-test p < 0.001).
This table shows molecular features associated with WASHC2A in patient tissues and cancer cell lines. In patient samples, WASHC2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, WASHC2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
